Disease-specific plasma levels of mitokines FGF21, GDF15, and Humanin in type II diabetes and Alzheimer's disease in comparison with healthy aging.
AD
Aging
FGF21
GDF15
Humanin
T2D
Journal
GeroScience
ISSN: 2509-2723
Titre abrégé: Geroscience
Pays: Switzerland
ID NLM: 101686284
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
31
07
2020
accepted:
13
10
2020
pubmed:
2
11
2020
medline:
1
6
2021
entrez:
1
11
2020
Statut:
ppublish
Résumé
Fibroblast Growth Factor 21 (FGF21), Growth Differentiation Factor 15 (GDF15), and Humanin (HN) are mitochondrial stress-related mitokines, whose role in health and disease is still debated. In this study, we confirmed that their plasma levels are positively correlated with age in healthy subjects. However, when looking at patients with type 2 diabetes (T2D) or Alzheimer's disease (AD), two age-related diseases sharing a mitochondrial impairment, we found that GDF15 is elevated in T2D but not in AD and represents a risk factor for T2D complications, while FGF21 and HN are lower in AD but not in T2D. Moreover, FGF21 reaches the highest levels in centenarian' offspring, a model of successful aging. As a whole, these data indicate that (i) the adaptive mitokine response observed in healthy aging is lost in age-related diseases, (ii) a common expression pattern of mitokines does not emerge in T2D and AD, suggesting an unpredicted complexity and disease-specificity, and (iii) FGF21 emerges as a candidate marker of healthy aging.
Identifiants
pubmed: 33131010
doi: 10.1007/s11357-020-00287-w
pii: 10.1007/s11357-020-00287-w
pmc: PMC8110619
doi:
Substances chimiques
GDF15 protein, human
0
Growth Differentiation Factor 15
0
Intracellular Signaling Peptides and Proteins
0
fibroblast growth factor 21
0
humanin
0
Fibroblast Growth Factors
62031-54-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
985-1001Références
Franceschi C, Garagnani P, Morsiani C, et al. The continuum of aging and age-related diseases: common mechanisms but different rates. Front Med (Lausanne). 2018;5:61. https://doi.org/10.3389/fmed.2018.00061 .
doi: 10.3389/fmed.2018.00061
Chen G, Kroemer G, Kepp O. Mitophagy: an emerging role in aging and age-associated diseases. Front Cell Dev Biol. 2020;8:200. https://doi.org/10.3389/fcell.2020.00200 .
doi: 10.3389/fcell.2020.00200
pubmed: 32274386
pmcid: 7113588
Natarajan V, Chawla R, Mah T, Vivekanandan R, Tan SY, Sato PY, et al. Mitochondrial dysfunction in age-related metabolic disorders. Proteomics. 2020;20:e1800404. https://doi.org/10.1002/pmic.201800404 .
doi: 10.1002/pmic.201800404
pubmed: 32131138
Durieux J, Wolff S, Dillin A. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell. 2011;144:79–91. https://doi.org/10.1016/j.cell.2010.12.016 .
doi: 10.1016/j.cell.2010.12.016
pubmed: 21215371
pmcid: 3062502
Conte M, Ostan R, Fabbri C, Santoro A, Guidarelli G, Vitale G, et al. Human aging and longevity are characterized by high levels of Mitokines. J Gerontol A Biol Sci Med Sci. 2019;74:600–7. https://doi.org/10.1093/gerona/gly153 .
doi: 10.1093/gerona/gly153
pubmed: 29955888
Conte M, Martucci M, Chiariello A, et al. Mitochondria, immunosenescence and inflammaging: a role for mitokines? Semin Immunopathol. in press. https://doi.org/10.1007/s00281-020-00813-0 .
Jayaraman A, Pike CJ. Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr Diab Rep. 2014;14:476. https://doi.org/10.1007/s11892-014-0476-2 .
doi: 10.1007/s11892-014-0476-2
pubmed: 24526623
pmcid: 3985543
Boccardi V, Murasecco I, Mecocci P. Diabetes drugs in the fight against Alzheimer's disease. Ageing Res Rev. 2019;54:100936. https://doi.org/10.1016/j.arr.2019.100936 .
doi: 10.1016/j.arr.2019.100936
pubmed: 31330313
Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer's disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol Basis Dis. 1863;2017:1078–89. https://doi.org/10.1016/j.bbadis.2016.08.018 .
doi: 10.1016/j.bbadis.2016.08.018
Cheng H, Gang X, Liu Y, Wang G, Zhao X, Wang G. Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes. Am J Physiol Endocrinol Metab. 2020;318:E750–64. https://doi.org/10.1152/ajpendo.00179.2019 .
doi: 10.1152/ajpendo.00179.2019
pubmed: 31714795
Rigotto G, Basso E. Mitochondrial dysfunctions: a thread sewing together Alzheimer's disease, diabetes, and obesity. Oxidative Med Cell Longev. 2019;2019:7210892–16. https://doi.org/10.1155/2019/7210892 . eCollection 2019. Review.
doi: 10.1155/2019/7210892
Zhang Y, Xie Y, Berglund ED, Coate KC, He TT, Katafuchi T, et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife. 2012;1:e00065. https://doi.org/10.7554/eLife.00065 .
doi: 10.7554/eLife.00065
pubmed: 23066506
pmcid: 3466591
Salminen A, Kaarniranta K, Kauppinen A. Regulation of longevity by FGF21: interaction between energy metabolism and stress responses. Ageing Res Rev. 2017;37:79–93. https://doi.org/10.1016/j.arr.2017.05.004 Review.
doi: 10.1016/j.arr.2017.05.004
pubmed: 28552719
Yu Y, He J, Li S, Song L, Guo X, Yao W, et al. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. Int Immunopharmacol. 2016;38:144–52. https://doi.org/10.1016/j.intimp.2016.05.026 .
doi: 10.1016/j.intimp.2016.05.026
pubmed: 27276443
Jia H, Cheng J, Zhou Q, Peng J, Pan Y, Han H. Fibroblast growth factor 21 attenuates inflammation and oxidative stress in atherosclerotic rat via enhancing the Nrf1-ARE signaling pathway. Int J Clin Exp Pathol. 2018;11:1308–17.
pubmed: 31938226
pmcid: 6958096
Tezze C, Romanello V, Sandri M. FGF21 as modulator of metabolism in health and disease. Front Physiol. 2019;10:419. https://doi.org/10.3389/fphys.2019.00419 .
doi: 10.3389/fphys.2019.00419
pubmed: 31057418
pmcid: 6478891
Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57:1246–53. https://doi.org/10.2337/db07-1476 [published correction appears in Diabetes. 2019 Jan;68(1):235].
doi: 10.2337/db07-1476
pubmed: 18252893
Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250–9. https://doi.org/10.2337/db08-0392 .
doi: 10.2337/db08-0392
pubmed: 18840786
pmcid: 2606881
So WY, Leung PS. Fibroblast growth factor 21 as an emerging therapeutic target for type 2 diabetes mellitus. Med Res Rev. 2016;36:672–704. https://doi.org/10.1002/med.21390 .
doi: 10.1002/med.21390
pubmed: 27031294
Restelli LM, Oettinghaus B, Halliday M, Agca C, Licci M, Sironi L, et al. Neuronal mitochondrial dysfunction activates the integrated stress response to induce fibroblast growth factor 21. Cell Rep. 2018;24:1407–14. https://doi.org/10.1016/j.celrep.2018.07.023 .
doi: 10.1016/j.celrep.2018.07.023
pubmed: 30089252
pmcid: 6092266
Taliyan R, Chandran SK, Kakoty V. Therapeutic approaches to Alzheimer's type of dementia: a focus on FGF21 mediated neuroprotection. Curr Pharm Des. 2019;25:2555–68. https://doi.org/10.2174/1381612825666190716101411 .
doi: 10.2174/1381612825666190716101411
pubmed: 31333086
Tanaka T, Biancotto A, Moaddel R, Moore AZ, Gonzalez-Freire M, Aon MA, et al. Plasma proteomic signature of age in healthy humans. Aging Cell. 2018;17:e12799. https://doi.org/10.1111/acel.12799 .
doi: 10.1111/acel.12799
pubmed: 29992704
pmcid: 6156492
Lehallier B, Gate D, Schaum N, Nanasi T, Lee SE, Yousef H, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med. 2019;25:1843–50. https://doi.org/10.1038/s41591-019-0673-2 .
doi: 10.1038/s41591-019-0673-2
pubmed: 31806903
pmcid: 7062043
Conte M, Martucci M, Mosconi G, Chiariello A, Cappuccilli M, Totti V, et al. GDF15 plasma level is inversely associated with level of physical activity and correlates with markers of inflammation and muscle weakness. Front Immunol. 2020;11:915. https://doi.org/10.3389/fimmu.2020.00915 .
doi: 10.3389/fimmu.2020.00915
pubmed: 32477368
pmcid: 7235447
Luan HH, Wang A, Hilliard BK, et al. GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance. Cell. 2019;178:1231–1244.e11.
doi: 10.1016/j.cell.2019.07.033
pubmed: 31402172
pmcid: 6863354
Moon JS, Goeminne LJE, Kim JT, et al. Growth differentiation factor 15 protects against the aging-mediated systemic inflammatory response in humans and mice. Aging Cell. 2020:e13195. https://doi.org/10.1111/acel.13195 .
Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res. 2015;2015:490842–14. https://doi.org/10.1155/2015/490842 . Review.
doi: 10.1155/2015/490842
pubmed: 26273671
pmcid: 4530250
Natali A, Nesti L, Venturi E, Shore AC, Khan F, Gooding K, et al. Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: a nested, case-control study. Diabetes Obes Metab. 2019;21(2):412–6. https://doi.org/10.1111/dom.13519 .
doi: 10.1111/dom.13519
pubmed: 30178545
Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003;423:456–61.
doi: 10.1038/nature01627
pubmed: 12732850
Thummasorn S, Shinlapawittayatorn K, Khamseekaew J, Jaiwongkam T, Chattipakorn SC, Chattipakorn N. Humanin directly protects cardiac mitochondria against dysfunction initiated by oxidative stress by decreasing complex I activity. Mitochondrion. 2018;38:31–40. https://doi.org/10.1016/j.mito.2017.08.001 .
doi: 10.1016/j.mito.2017.08.001
pubmed: 28802666
Zhao ST, Zhao L, Li JH. Neuroprotective peptide humanin inhibits inflammatory response in astrocytes induced by lipopolysaccharide. Neurochem Res. 2013;38:581–8. https://doi.org/10.1007/s11064-012-0951-6 .
doi: 10.1007/s11064-012-0951-6
pubmed: 23277413
Muzumdar RH, Huffman DM, Atzmon G, Buettner C, Cobb LJ, Fishman S, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009;4(7):e6334. https://doi.org/10.1371/journal.pone.0006334 .
doi: 10.1371/journal.pone.0006334
pubmed: 19623253
pmcid: 2709436
Lee C, Wan J, Miyazaki B, Fang Y, Guevara-Aguirre J, Yen K, et al. IGF-I regulates the age-dependent signaling peptide humanin. Aging Cell. 2014;13(5):958–61. https://doi.org/10.1111/acel.12243 .
doi: 10.1111/acel.12243
pubmed: 25040290
pmcid: 4172517
Salemi M, Ridolfo F, Salluzzo MG, Cannarrella R, Giambirtone M, Caniglia S, et al. Humanin gene expression in fibroblast of Down syndrome subjects. Int J Med Sci. 2020;17(3):320–4. https://doi.org/10.7150/ijms.39145 .
doi: 10.7150/ijms.39145
pubmed: 32132866
pmcid: 7053358
Terry DF, Wilcox MA, McCormick MA, et al. Lower all-cause, cardiovascular, and cancer mortality in centenarians' offspring. J Am Geriatr Soc. 2004;52:2074–6.
doi: 10.1111/j.1532-5415.2004.52561.x
pubmed: 15571545
Bucci L, Ostan R, Cevenini E, et al. Centenarians' offspring as a model of healthy aging: a reappraisal of the data on Italian subjects and a comprehensive overview. Aging (Albany NY). 2016;8:510–9. https://doi.org/10.18632/aging.100912 .
doi: 10.18632/aging.100912
Testa R, Vanhooren V, Bonfigli AR, Boemi M, Olivieri F, Ceriello A, et al. N-glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One. 2015;10(3):e0119983. https://doi.org/10.1371/journal.pone.0119983 .
doi: 10.1371/journal.pone.0119983
pubmed: 25793407
pmcid: 4368037
Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017;49(9):1373–84. https://doi.org/10.1038/ng.3916 .
doi: 10.1038/ng.3916
pubmed: 28714976
pmcid: 5669039
Mensà E, Giuliani A, Matacchione G, Gurău F, Bonfigli AR, Romagnoli F, et al. Circulating miR-146a in healthy aging and type 2 diabetes: age- and gender-specific trajectories. Mech Ageing Dev. 2019;180:1–10. https://doi.org/10.1016/j.mad.2019.03.001 .
doi: 10.1016/j.mad.2019.03.001
pubmed: 30880174
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 .
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.
doi: 10.2307/2531595
pubmed: 3203132
Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116(1):65–8. https://doi.org/10.1055/s-2007-985148 .
doi: 10.1055/s-2007-985148
pubmed: 17926232
Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32(8):1542–6.
doi: 10.2337/dc09-0684
pubmed: 19487637
pmcid: 2713625
Wang YS, Ye J, Cao YH, Zhang R, Liu Y, Zhang SW, et al. Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta-analysis. Postgrad Med J. 2019;95(1121):134–9. https://doi.org/10.1136/postgradmedj-2018-136002 .
doi: 10.1136/postgradmedj-2018-136002
pubmed: 30918117
Schnurr TM, Jakupović H, Carrasquilla GD, et al. Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: a case-cohort study [published online ahead of print, 2020 Apr 15]. Diabetologia. 2020. https://doi.org/10.1007/s00125-020-05140-5 .
Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance [published correction appears in Nature. 2020;578(7795):444–448. https://doi.org/10.1038/s41586-019-1911-y .
Calanna S, Scicali R, Di Pino A, et al. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014;24:670–6. https://doi.org/10.1016/j.numecd.2014.01.013 .
doi: 10.1016/j.numecd.2014.01.013
pubmed: 24656139
Scicali R, Di Pino A, Ferrara V, et al. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Acta Diabetol. 2018;55:209–18. https://doi.org/10.1007/s00592-017-1089-4 .
doi: 10.1007/s00592-017-1089-4
pubmed: 29260404
Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 1992;231:25–30. https://doi.org/10.1111/j.1365-2796.1992.tb00494.x .
doi: 10.1111/j.1365-2796.1992.tb00494.x
pubmed: 1732395
Scicali R, Giral P, D'Erasmo L, Cluzel P, Redheuil A, di Pino A, et al. High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects. Diabetes Metab Res Rev. 2020;18:e3367. https://doi.org/10.1002/dmrr.3367 .
doi: 10.1002/dmrr.3367
Carlsson AC, Nowak C, Lind L, Östgren CJ, Nyström FH, Sundström J, et al. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2020;125:37–43. https://doi.org/10.1080/03009734.2019.1696430 .
doi: 10.1080/03009734.2019.1696430
pubmed: 31805809
Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care. 2019;42(3):416–26. https://doi.org/10.2337/dc17-1144 .
doi: 10.2337/dc17-1144
pubmed: 30104301
Lai YR, Huang CC, Chiu WC, Liu RT, Tsai NW, Wang HC, et al. HbA1C variability is strongly associated with the severity of cardiovascular autonomic neuropathy in patients with type 2 diabetes after longer diabetes duration. Front Neurosci. 2019;13:458. https://doi.org/10.3389/fnins.2019.00458 .
doi: 10.3389/fnins.2019.00458
pubmed: 31139045
pmcid: 6527872
Simonovitch S, Schmukler E, Masliah E, Pinkas-Kramarski R, Michaelson DM. The effects of APOE4 on mitochondrial dynamics and proteins in vivo. J Alzheimers Dis. 2019;70:861–75. https://doi.org/10.3233/JAD-190074 .
doi: 10.3233/JAD-190074
pubmed: 31306119
pmcid: 7478177
He K, Nie L, Zhou Q, Rahman SU, Liu J, Yang X, et al. Proteomic profiles of the early mitochondrial changes in APP/PS1 and ApoE4 transgenic mice models of Alzheimer's disease. J Proteome Res. 2019;18:2632–42. https://doi.org/10.1021/acs.jproteome.9b00136 .
doi: 10.1021/acs.jproteome.9b00136
pubmed: 31055927
Farmer BC, Kluemper J, Johnson LA. Apolipoprotein E4 alters astrocyte fatty acid metabolism and lipid droplet formation. Cells. 2019;8(2):182. https://doi.org/10.3390/cells8020182 .
doi: 10.3390/cells8020182
pmcid: 6406677
Mottis A, Herzig S, Auwerx J. Mitocellular communication: shaping health and disease. Science. 2019;366(6467):827–32. https://doi.org/10.1126/science.aax3768 .
doi: 10.1126/science.aax3768
pubmed: 31727828
Gong Z, Tas E, Muzumdar R. Humanin and age-related diseases: a new link? Front Endocrinol (Lausanne). 2014;5:210. https://doi.org/10.3389/fendo.2014.00210 .
doi: 10.3389/fendo.2014.00210
Ji X, Zhao L, Ji K, Zhao Y, Li W, Zhang R, et al. Growth differentiation factor 15 is a novel diagnostic biomarker of mitochondrial diseases. Mol Neurobiol. 2017;54:8110–6. https://doi.org/10.1007/s12035-016-0283-7 .
doi: 10.1007/s12035-016-0283-7
pubmed: 27889897
Scholle LM, Lehmann D, Deschauer M, Kraya T, Zierz S. FGF-21 as a potential biomarker for mitochondrial diseases. Curr Med Chem. 2018;25:2070–81. https://doi.org/10.2174/0929867325666180111094336 .
doi: 10.2174/0929867325666180111094336
pubmed: 29332568
De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014;63:2262–72. https://doi.org/10.2337/db13-1954 .
doi: 10.2337/db13-1954
pubmed: 24931033
Sun Y, Ma C, Sun H, et al. Metabolism: a novel shared link between diabetes mellitus and Alzheimer's disease. J Diabetes Res. 2020;2020:4981814. Published 2020 Jan 29. https://doi.org/10.1155/2020/4981814 .
doi: 10.1155/2020/4981814
pubmed: 32083135
pmcid: 7011481
Wang KC, Woung LC, Tsai MT, Liu CC, Su YH, Li CY. Risk of Alzheimer's disease in relation to diabetes: a population-based cohort study. Neuroepidemiology. 2012;38:237–44. https://doi.org/10.1159/000337428 .
doi: 10.1159/000337428
pubmed: 22572745
Berezin AE. Diabetes mellitus related biomarker: the predictive role of growth-differentiation factor-15. Diabetes Metab Syndr. 2016;10:S154–7. https://doi.org/10.1016/j.dsx.2015.09.016 .
doi: 10.1016/j.dsx.2015.09.016
pubmed: 26482961
Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, Lee MH, et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology. 2013;154:3366–76. https://doi.org/10.1210/en.2012-2276 .
doi: 10.1210/en.2012-2276
pubmed: 23825123
Jimenez V, Jambrina C, Casana E, et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med. 2018;10:e8791. https://doi.org/10.15252/emmm.201708791 .
doi: 10.15252/emmm.201708791
pubmed: 29987000
pmcid: 6079533
Santoso P, Nakata M, Shiizaki K, Boyang Z, Parmila K, Otgon-Uul Z, et al. Fibroblast growth factor 21, assisted by elevated glucose, activates paraventricular nucleus NUCB2/Nesfatin-1 neurons to produce satiety under fed states. Sci Rep. 2017;7:45819. https://doi.org/10.1038/srep45819 .
doi: 10.1038/srep45819
pubmed: 28374855
pmcid: 5379189
Voigt A, Jelinek HF. Humanin: a mitochondrial signaling peptide as a biomarker for impaired fasting glucose-related oxidative stress. Phys Rep. 2016;4:e12796. https://doi.org/10.14814/phy2.12796 .
doi: 10.14814/phy2.12796
Ramanjaneya M, Bettahi I, Jerobin J, et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front Endocrinol (Lausanne). 2019;10:331. https://doi.org/10.3389/fendo.2019.00331 .
doi: 10.3389/fendo.2019.00331
Chai YL, Hilal S, Chong JP, et al. Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia. Medicine (Baltimore). 2016;95:e4566. https://doi.org/10.1097/MD.0000000000004566 .
doi: 10.1097/MD.0000000000004566
Maetzler W, Deleersnijder W, Hanssens V, Bernard A, Brockmann K, Marquetand J, et al. GDF15/MIC1 and MMP9 cerebrospinal fluid levels in Parkinson's disease and Lewy body dementia. PLoS One. 2016;11:e0149349. https://doi.org/10.1371/journal.pone.0149349 .
doi: 10.1371/journal.pone.0149349
pubmed: 26938614
pmcid: 4777571
Yao X, Wang D, Zhang L, Wang L, Zhao Z, Chen S, et al. Serum growth differentiation factor 15 in Parkinson disease. Neurodegener Dis. 2017;17:251–60. https://doi.org/10.1159/000477349 .
doi: 10.1159/000477349
pubmed: 28787735
Chen S, Chen ST, Sun Y, Xu Z, Wang Y, Yao SY, et al. Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer's disease. Redox Biol. 2019;22:101133. https://doi.org/10.1016/j.redox.2019.101133 .
doi: 10.1016/j.redox.2019.101133
pubmed: 30785085
pmcid: 6383137
Osorio RS, Pirraglia E, Agüera-Ortiz LF, During EH, Sacks H, Ayappa I, et al. Greater risk of Alzheimer's disease in older adults with insomnia. J Am Geriatr Soc. 2011;59:559–62. https://doi.org/10.1111/j.1532-5415.2010.03288.x .
doi: 10.1111/j.1532-5415.2010.03288.x
pubmed: 21391952
pmcid: 3378676
Martucci M, Conte M, Ostan R, et al. Both objective and paradoxical insomnia elicit a stress response involving mitokine production. Aging (Albany NY). 2020;12:10497–505. https://doi.org/10.18632/aging.103274 .
doi: 10.18632/aging.103274
Hashimoto Y, Niikura T, Ito Y, Sudo H, Hata M, Arakawa E, et al. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults. J Neurosci. 2001;21:9235–45. https://doi.org/10.1523/JNEUROSCI.21-23-09235.2001 .
doi: 10.1523/JNEUROSCI.21-23-09235.2001
pubmed: 11717357
pmcid: 6763898
Chai GS, Duan DX, Ma RH, Shen JY, Li HL, Ma ZW, et al. Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats. Neurosci Bull. 2014;30:923–35. https://doi.org/10.1007/s12264-014-1479-3 .
doi: 10.1007/s12264-014-1479-3
pubmed: 25391447
pmcid: 5562564
Yen K, Wan J, Mehta HH, et al. Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans. Sci Rep. 2018;8:14212. Published 2018 Sep 21. https://doi.org/10.1038/s41598-018-32616-7 .
doi: 10.1038/s41598-018-32616-7
pubmed: 30242290
pmcid: 6154958
Yen K, Mehta HH, Kim SJ, et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020;12:11185–99. https://doi.org/10.18632/aging.103534 .
doi: 10.18632/aging.103534
Bachar AR, Scheffer L, Schroeder AS, Nakamura HK, Cobb LJ, Oh YK, et al. Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress. Cardiovasc Res. 2010;88:360–6. https://doi.org/10.1093/cvr/cvq191 .
doi: 10.1093/cvr/cvq191
pubmed: 20562421
pmcid: 2952532
Widmer RJ, Flammer AJ, Herrmann J, Rodriguez-Porcel M, Wan J, Cohen P, et al. Circulating humanin levels are associated with preserved coronary endothelial function. Am J Physiol Heart Circ Physiol. 2013;304:H393–7. https://doi.org/10.1152/ajpheart.00765.2012 .
doi: 10.1152/ajpheart.00765.2012
pubmed: 23220334